Icon

ALOXI (nda021372)- (EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML),EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML))

PALONOSETRON HYDROCHLORIDE HELSINN HLTHCARE
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML),EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)
Yes No
2024-Jul-30 Expired
None None
None No
Aloxi is indicated for: 1) the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, and 2) the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
17 2 16
Total Other Developers None
Drugs with Suitability No
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) ** ** - - -
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 16
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** *** **** ************** ********** ***. *********** ** *** ******* ******, ********** ****, **** ****, *******, ****** (***) ***
****** ** ****** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ****** ******** ************ ****** ***. *********** *** *** *****-***** ******, ************, ** *** ***, ****** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ****, *****, ***, ************, ********** ******, **********, ********* ******, ***** (***) ***
****** **** ***** ****** **** ************** (******) **., ***. *********** **.***-*, ****** ******, ******** ****-**** ****, ******, ****** ******, ***** (***) ***
****** ***** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ************* ***** ******** *********** *******, ** ******, , ******* (***) ***
****** ********* **** *** ********* **** ******* *********** ************* ** ** ** *********** *, ****, ********, ******* ****, ****, ******* (***) ***
****** ********* **** *** ********* **** ******* *********** ************* ** ** ** *********** *, ****, ********, ******* ****, ****, ******* (***) ***
****** ****** ******** **** ****** ******** **** *********** *********** *, *****/*********, *****, ******* (***) ***
****** ****** **** ****** ******** ******* *********** *** *****-** & ***, *-**,**,**, ***** ********** ****, *****,, ***, *** ******, ***** (***) ***
****** ********* ** ****** *.*. *********** ***** *****-***** ***** *****, *******, ****** *****, ****** (***) ***
****** **** ************ ****** *************** ******* *********** **** **. **-**, ** & **/*, ****, ****** - **, ******, *** - ******, *********, ******* ******, ***** (***) ***
****** ******* ****-****** ******* ****-****** *********** ************** **.,***. (*** ****) *********** **, ** ***** ****, ******* **** *** *** ********** *********** **** ******* ******, *******, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.